Quick Answer
Cartesian Therapeutics, Inc. reported Stockholders Equity of -$126.24 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed a decrease of -1,755.9% in Stockholders Equity from 2024 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2016: $68.78 million | Q3 2016: $65.44 million | Q1 2017: $41.09 million | Q2 2017: $78.18 million | Q3 2017: $65.08 million | Q1 2018: $38.98 million | Q2 2018: $21.66 million | Q3 2018: $7.40 million | Q1 2019: $14.82 million | Q2 2019: $56.0 thousand | Q3 2019: -$4.92 million | Q1 2020: -$8.76 million | Q2 2020: -$13.05 million | Q3 2020: -$7.38 million | Q1 2021: -$19.57 million | Q2 2021: -$4.22 million | Q3 2021: -$18.73 million | Q1 2022: $55.76 million | Q2 2022: $89.61 million | Q3 2022: $84.91 million | Q1 2023: $74.58 million | Q2 2023: $65.45 million | Q3 2023: $60.33 million | Q1 2024: -$116.80 million | Q2 2024: -$101.46 million | Q3 2024: $752.0 thousand | Q1 2025: -$21.79 million | Q2 2025: -$2.53 million | Q3 2025: -$35.84 million.
- Over the full 13 years of available data (2013 to 2025), Cartesian Therapeutics, Inc.'s Stockholders Equity has declined by 81.7%.
- Historical annual values: Fiscal year 2025: -$126.24 million | Fiscal year 2024: -$6.80 million | Fiscal year 2023: -$440.18 million | Fiscal year 2022: $93.83 million | Fiscal year 2021: $22.52 million | Fiscal year 2020: -$18.01 million | Fiscal year 2019: $8.40 million | Fiscal year 2018: -$5.42 million | Fiscal year 2017: $51.81 million | Fiscal year 2016: $54.96 million | Fiscal year 2015: -$116.49 million | Fiscal year 2014: -$87.76 million | Fiscal year 2013: -$69.46 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: